Latest news with #Based
Yahoo
14 hours ago
- Business
- Yahoo
$1.13 Bn Polymer Based Wound Dressings Markets - Global Industry Size, Share, Trends, Opportunities, and Forecasts, 2020-2030F
Key market opportunities in polymer-based wound dressings include the rise in demand for advanced wound care products, potential for personalized dressings, smart sensor integration, and digital health ecosystems. Expanding applications in chronic and acute wound management also offer growth potential, especially when aligned with evolving clinical protocols. Polymer Based Wound Dressings Market Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Polymer Based Wound Dressings Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to Polymer Based Wound Dressings Market was valued at USD 0.89 Billion in 2024, and is expected to reach USD 1.13 Billion by 2030, rising at a CAGR of 4.15% The global polymer-based wound dressings market is witnessing strong expansion, underpinned by rising demand for sophisticated wound care products that improve healing efficiency and mitigate infection risks. These dressings capitalize on polymer technologies to deliver enhanced moisture management, adaptability, and inherent antimicrobial properties, setting them apart from conventional wound care options. The market contends with pricing constraints in emerging markets, complex regulatory pathways, and the imperative for rigorous clinical validation to facilitate widespread adoption of novel products. However, significant opportunities exist in advancing personalized wound dressings, integrating smart sensor technologies, and leveraging digital health ecosystems to optimize wound management expanding indications spanning chronic wound care and post-surgical applications are broadening market scope. Organizations that strategically invest in innovation aligned with evolving clinical protocols and cost-efficiency imperatives will be best positioned to capture enhanced market share amid intensifying competition and shifting healthcare delivery Incidence of Chronic and Acute WoundsThe global prevalence of chronic wounds is estimated between 1.51 to 2.21 per 1,000 individuals, creating a sizeable and addressable market for advanced wound care wounds typically exhibit delayed healing, recurrence, and a high infection risk, requiring long-term interventions where skin substitutes serve as critical enablers of accelerated tissue regeneration. As clinical demand for durable and biologically active wound closure options increases, skin substitutes are becoming a first-line intervention in chronic wound protocols, displacing traditional, less effective dressings. Their ability to minimize complications, reduce healing time, and improve outcomes positions them as essential tools in value-based wound management Complexity and Lack of Harmonized StandardsOne of the most pressing challenges is the lack of standardized and harmonized regulatory frameworks for plant-based APIs across global APIs are often categorized differently across regions ranging from herbal medicines to dietary supplements or even traditional remedies. This inconsistency complicates product registration, labeling, and market entry, particularly in regulated markets such as the U.S., EU, and Japan. Unlike synthetic APIs, which follow well-defined approval pathways, plant-based APIs require complex documentation of botanical origin, bioactive compound consistency, and clinical efficacy, which can vary depending on the source and preparation method. Complying with multiple sets of regulatory standards increases time-to-market and operational costs, particularly for SMEs and regional manufacturers attempting to scale globally. This fragmented regulatory environment creates uncertainty for investors and developers, slowing R&D and international of Phytopharmaceuticals into Mainstream Drug DevelopmentA significant trend reshaping the plant-based API market is the growing integration of phytopharmaceuticals into conventional drug pipelines. Historically, plant-based compounds were largely confined to traditional medicine or nutraceutical applications. However, this is changing as pharmaceutical companies recognize their potential for targeted therapeutic action with fewer side effects.A rising number of plant-derived compounds are undergoing clinical trials, validating their efficacy for chronic and lifestyle-related diseases such as diabetes, cardiovascular disorders, cancer, and neurodegenerative conditions. Major pharmaceutical firms are partnering with biotech startups and research institutes to co-develop plant-based drugs leveraging natural product libraries for lead discovery and screening. Advances in extraction, purification, and delivery systems have allowed for the development of proprietary formulations, making plant-based APIs commercially attractive due to stronger IP protections and differentiated value trend signifies a paradigm shift in pharma innovation, where nature-based APIs are no longer peripheral but are being strategically positioned within modern therapeutics. Key Attributes: Report Attribute Details No. of Pages 180 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $0.89 Billion Forecasted Market Value (USD) by 2030 $1.13 Billion Compound Annual Growth Rate 4.1% Regions Covered Global Report Scope: Competitive LandscapeCompany Profiles: Detailed analysis of the major companies present in the Global Polymer Based Wound Dressings Market. 3M Company Coloplast A/S HRA Pharma SAS Covalon Technologies, Ltd. Smith & Nephew Plc. Sorbsan ConvaTec Limited Pfizer, Inc. (Pharmacia) Molnlycke Healthcare AB Polymer Based Wound Dressings Market, By Type: Films Foams Hydrogels Alginates Others Polymer Based Wound Dressings Market, By Mechanism: Antimicrobial Immunostimulant Others Polymer Based Wound Dressings Market, By Application: Burns Chronic Wounds Skin Injuries Ulcers Others Polymer Based Wound Dressings Market, By End User: Hospitals & Clinics Ambulatory Surgery Centers Others Polymer Based Wound Dressings Market, By Region: North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Polymer Based Wound Dressings Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
27-05-2025
- Business
- Yahoo
Universal Corporation's GHG Emissions Target Approved by SBTi
RICHMOND, Va., May 27, 2025--(BUSINESS WIRE)--Universal Corporation (NYSE:UVV), a global business-to-business agriproducts company, announced its ambitious Net-Zero target has been approved by the Science Based Target initiative (SBTi). This significant achievement underscores Universal's commitment to sustainable business practices and its proactive approach to mitigating climate-related impacts. The SBTi approval confirms that Universal Corporation's current net-zero target meets the rigorous criteria set by the initiative. This target is part of Universal's broader sustainability strategy, which includes reducing greenhouse gas (GHG) emissions across its entire value chain and investing in innovative solutions to mitigate the Company's environmental impact. Specifically, Universal Corporation has committed to: Overall Net-Zero target: Reach net-zero greenhouse gas (GHG) emissions across the value chain by 2050 Near-term targets: A 45 percent reduction in absolute scope 1 and 2 GHG emissions by 2030 as compared to 2024 A 25 percent reduction in absolute scope 3 GHG emissions from purchased goods and services, capital goods, waste generated in operations, business travel, processing of sold products, and use of sold products within the same timeframe Long-term target: A 90 percent reduction in absolute scope 1, 2 and 3 GHG emissions by 2050 as compared to 2024 Universal Corporation also commits to no deforestation across its primary deforestation-linked commodities by December 2025. These targets are part of Universal's broader sustainability strategy, which include reducing greenhouse gas (GHG) emissions across its entire value chain and investing in innovative solutions to mitigate environmental impact. Preston D. Wigner, Chairman, President, and Chief Executive Officer of Universal, said, "Sustainability is good for our business and is good stewardship in the communities in which we operate. Our business strategy integrates responsible business practices, and we believe our commitment to sustainability is a competitive advantage in the global marketplace. The approval of our net-zero target by the SBTi is a testament to our ability to drive positive business results while making a positive commitment to stewardship." About the Science Based Targets initiative The Science Based Targets initiative (SBTi) is a global body enabling businesses to set ambitious emissions reductions targets in line with the latest climate science. It is focused on accelerating companies across the world to halve emissions before 2030 and achieve net-zero emissions before 2050. Partner organizations who facilitated SBTi's growth and development are CDP, the United Nations Global Compact, the We Mean Business Coalition, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF). SBTi defines and promotes best practice in science-based target setting, offers resources and guidance to reduce barriers to adoption, and independently assesses and approves companies' targets. About Universal Corporation Universal Corporation (NYSE: UVV) is a global agricultural company with over 100 years of experience supplying products and innovative solutions to meet our customers' evolving needs and precise specifications. Through our diverse network of farmers and partners across more than 30 countries on five continents, we are a trusted provider of high-quality, traceable products. We leverage our extensive supply chain expertise, global reach, integrated processing capabilities, and commitment to sustainability to provide a range of products and services designed to drive efficiency and deliver value to our customers. For more information, visit View source version on Contacts Universal Corporation Investor RelationsPhone: (804) 359-9311Fax: (804) 254-3584Email: investor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
22-04-2025
- Business
- Associated Press
WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
SHANGHAI, April 22, 2025 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') ( a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized by CDP, the world's foremost environmental non-profit reporting organization, for its leadership in disclosure transparency and performance excellence in the area of climate change. This marks the second consecutive year the company has achieved this honor. CDP is recognized as the global standard for corporate environmental reporting, and its annually published ratings are widely used to drive investment and procurement decisions toward a net-zero, sustainable and resilient economy. Companies are evaluated on their awareness of environmental issues, management methods and advancements in environmental stewardship. In 2024, nearly 25,000 companies — representing two-thirds of the global market value — reported their environmental data through CDP. WuXi Biologics stood out among these companies with an 'A-" score for leadership on climate change. Committed to the Science Based Target initiative (SBTi), WuXi Biologics has adopted an integrated strategy to tackle climate change issues, with measurable targets and a refined roadmap. The Company aims to achieve net-zero emissions from overall operations by 2050, and in 2024, it realized a 30% GHG (Scope 1 and Scope 2) emission intensity reduction from the base year 2020. The company also actively pursues opportunities to decrease energy consumption, advocating energy-saving initiatives from process optimization, equipment upgrade, and infrastructure replacement and renovation. The company actively deploys rooftop photovoltaic power projects, and has achieved a 100% renewable electricity supply at its Ireland site. Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, 'We are very pleased to be recognized once again by CDP for climate change leadership, an acknowledgement that further inspires our steadfast dedication to enhancing our sustainability performance. It is fitting that we are making this announcement on Earth Day as we, along with organizations and communities around the world, put special focus on the importance of long-term ecological sustainability. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide with end-to-end solutions to fulfil their ESG commitments, and work together with all of our stakeholders to promote responsible practices throughout the entire value chain.' As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability, and has earned widespread recognition for its efforts. It was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI) for two consecutive years; included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; merited an 'A' CDP Water Security score; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating. About CDP CDP is a global non-profit that runs the world's only independent environmental disclosure system. As the founder of environmental reporting, the organization believes in transparency and the power of data to drive change. Partnering with leaders in enterprise, capital, policy and science, CDP surfaces the information needed to enable Earth-positive decisions. It helped more than 24,800 companies and 1,100 cities, states and regions disclose their environmental impacts in 2024. Financial institutions with more than a quarter of the world's institutional assets use CDP data to help inform investment and lending decisions. Aligned with the ISSB's climate standard, IFRS S2, as its foundational baseline, CDP integrates best-practice reporting standards and frameworks in one place. The team is truly global, united by a shared desire to build a world where people, planet and profit are truly balanced. About WuXi Biologics WuXi Biologics (stock code: is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects). WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain. For more information about WuXi Biologics, please visit: View original content: SOURCE WuXi Biologics
BBC News
13-02-2025
- Politics
- BBC News
East Sussex: Plans to change how council housing is allocated
Councils in Lewes and Eastbourne are proposing a new approach to the way council homes are allocated to residents on waiting are recommending moving away from the current bidding system to a new method that enables housing officers to match homes to the best-suited families and individuals on the show that in 2022/23 there were 529 households on the waiting list in Lewes and 179 properties available, while in Eastbourne there were 823 households and 181 in Lewes agreed to push ahead with the plans last week and launch a public consultation, with the same proposals to be discussed in Eastbourne later. 'Positive step forward' Choice-based lettings (CBL) was introduced by the government in 2001 and councils were offered grant funding as an incentive to adopt the bidding process takes two weeks before applicants can be councils say, as demand has outstripped supply and many applicants spend years on the waiting list, the CBL model causes significant delays that can leave available properties empty for several has been estimated only 60% of those on the housing register bid for properties and applicants are not encouraged to broaden areas of choice to improve their chances of Mark Slater, Lewes District Council cabinet member for tenants and those in housing needs, said while a new system would not solve the "deep rooted-issues" of the availability of social housing, it would be a "very positive step forward".He added: "I see numerous advantages of Property Match over Choice Based Lettings, most notably the speed of the process, the greater clarity and transparency and much improved customer service." If adopted, applicants would continue to be prioritised into bands A-C, with priority also based on their registration date, bedroom need, disabled adaptations and their preferred local include some adjustment to the bandings, introducing a maximum income threshold of £80,000 and a housing-related debt limit of £1,500 to qualify to join the housing would still be able to express a preference for where they would like to live, have the right to decline the first two offers made without any impact on their status on the register and continue to be able to challenge the reasonableness of offers they receive.
